down arrow

Carmell Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1429221039
USD
0.39
0.02 (5.16%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.390.55

52 Week

0.3736.00
Valuation
Technical
Day's Volume

CASH

646

Shareholding (Mar 2025)

FII

9.12%

Held by 10 FIIs

DII

89.58%

Held by 1 DIIs

Promoter

0.00%

How big is Carmell Corp.?

22-Jun-2025

As of Jun 18, Carmell Corp. has a market capitalization of 2.28 million, with net sales of 0.56 million and a net profit of -8.60 million over the last four quarters. Shareholder's funds are at -4.71 million, and total assets are 1.47 million as of Dec 24.

As of Jun 18, Carmell Corp. has a market capitalization of 2.28 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.56 million, while the sum of Net Profit for the same period is -8.60 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at -4.71 million and Total Assets at 1.47 million.

Read More

What does Carmell Corp. do?

22-Jun-2025

Carmell Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $1 million and a net loss of $2 million. It has a market cap of $2.28 million and key metrics indicating a high return on equity but no dividends or earnings due to losses.

Overview: <BR>Carmell Corp. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2.28 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.14 <BR>Return on Equity: 131.79% <BR>Price to Book: -0.60<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Carmell Corp. overvalued or undervalued?

25-Jun-2025

As of March 31, 2025, Carmell Corp. is overvalued and classified as "does not qualify" due to a negative P/E ratio and poor financial metrics, including a Price to Book Value of -0.72, while its year-to-date return of -67.87% starkly contrasts with the S&P 500's gain of 2.44%.

As of 31 March 2025, the valuation grade for Carmell Corp. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently overvalued, given its negative P/E ratio and other concerning metrics. Key ratios include a Price to Book Value of -0.72, an EV to EBIT of -0.43, and an EV to EBITDA of -0.45, all of which reflect the company's struggles.<BR><BR>In comparison to its peers, Carmell Corp. shows a less favorable position, with its EV to EBITDA ratio of -0.4545 compared to Immunome, Inc. at -2.5424 and CARA Therapeutics, Inc. at -8.0086, both of which are also classified as risky. The company's stock performance has been dismal, with a year-to-date return of -67.87%, contrasting sharply with the S&P 500's modest gain of 2.44%. This further reinforces the notion that Carmell Corp. is not only overvalued but also facing significant operational challenges.

Read More

Is Carmell Corp. technically bullish or bearish?

25-Jun-2025

As of June 17, 2025, Carmell Corp. has shifted to a bearish trend, supported by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals on longer time frames.

As of 17 June 2025, the technical trend for Carmell Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength. Key indicators driving this stance include the daily moving averages which are bearish, the weekly and monthly Bollinger Bands indicating bearish trends, and Dow Theory confirming a bearish outlook in both weekly and monthly time frames. While the MACD shows mildly bullish signals on the weekly and monthly, this is overshadowed by the overall bearish indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.99
  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2

Risky - Negative EBITDA

3

Reducing Promoter Confidence

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.39

stock-summary
Return on Equity

152.26%

stock-summary
Price to Book

-1.20

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-83.98%
0%
-83.98%
6 Months
-86.76%
0%
-86.76%
1 Year
-96.01%
0%
-96.01%
2 Years
-99.57%
0%
-99.57%
3 Years
-96.07%
0%
-96.07%
4 Years
-95.98%
0%
-95.98%
5 Years
0%
0%
0.0%

Carmell Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Carmell Corp. Stock Plummets to New 52-Week Low of $0.82

Carmell Corp. Stock Plummets to New 52-Week Low of $0.82

Carmell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a difficult year with a significant stock price decline. The company, with a market cap of approximately USD 4 million, has not reported earnings and shows a moderate debt-to-equity ratio.

Read More
Carmell Corp. Stock Plummets to New 52-Week Low of $1.12

Carmell Corp. Stock Plummets to New 52-Week Low of $1.12

Carmell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a significant decline over the past year. With a market capitalization of around USD 4 million, the company is currently loss-making and faces valuation concerns despite a high return on equity.

Read More
Carmell Corp. Hits New 52-Week Low at $1.21 Amidst Declining Performance

Carmell Corp. Hits New 52-Week Low at $1.21 Amidst Declining Performance

Carmell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company reports negative earnings, a negative book value, and consistent losses, raising concerns about its financial stability and future prospects.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
15.44%
EBIT Growth (5y)
-236.79%
EBIT to Interest (avg)
-2.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.14
Sales to Capital Employed (avg)
-1.17
Tax Ratio
1.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
40.20%
ROCE (avg)
0
ROE (avg)
0.05%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.72
EV to EBIT
-0.43
EV to EBITDA
-0.45
EV to Capital Employed
-0.51
EV to Sales
2.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (1.3%)

Foreign Institutions

Held by 10 Foreign Institutions (9.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 42.42% vs -1,200.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "-1.10",
          "chgp": "-63.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-2.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.90",
          "val2": "-3.30",
          "chgp": "42.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,690.50%",
          "val2": "-96,711.60%",
          "chgp": "9,302.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 33.95% vs -78.02% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.80",
          "val2": "-5.10",
          "chgp": "5.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.70",
          "val2": "-10.20",
          "chgp": "44.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.70",
          "val2": "-16.20",
          "chgp": "33.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-99,338.20%",
          "val2": "0.00%",
          "chgp": "-9,933.82%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.50
0.00
Operating Profit (PBDIT) excl Other Income
-1.80
-1.10
-63.64%
Interest
0.00
0.00
Exceptional Items
-0.00
-2.10
100.00%
Consolidate Net Profit
-1.90
-3.30
42.42%
Operating Profit Margin (Excl OI)
-3,690.50%
-96,711.60%
9,302.11%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 42.42% vs -1,200.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-4.80
-5.10
5.88%
Interest
0.00
0.90
-100.00%
Exceptional Items
-5.70
-10.20
44.12%
Consolidate Net Profit
-10.70
-16.20
33.95%
Operating Profit Margin (Excl OI)
-99,338.20%
0.00%
-9,933.82%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 33.95% vs -78.02% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Carmell Corp. stock-summary
stock-summary
Carmell Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."